Defence Fortifies Patent Portfolio
Defence Therapeutics (DTCFF) has strengthened its patent portfolio with multiple key patent issuances and allowances. The USPTO issued a Notice of Allowance for US patent application 18/318,384, filed in May 2023, covering Accum®-based dimers and multimers. This patent, expected in early 2025, will provide market exclusivity until 2043 for Defence's AccuTOX® and ARM® anti-cancer programs.
The company also secured US patent 12,150,989 on November 26, 2024, extending protection of Accum®-based immunogenicity-enhancing variants to steroid acid-based compounds. Additionally, a Singaporean patent application was recently allowed and is expected to be granted in early 2025.
These developments strengthen Defence's intellectual property position for licensing and strategic partnerships, particularly in improving vaccine potency. The company plans additional national patent filings in Q3 2025 through PCT application PCT/CA2023/051758.
Defence Therapeutics (DTCFF) ha rafforzato il proprio portafoglio brevetti con numerosi importanti conferimenti e approvazioni di brevetti. L'USPTO ha emesso un Avviso di Approvazione per la domanda di brevetto statunitense 18/318,384, depositata a maggio 2023, che copre dimers e multimers a base di Accum®. Questo brevetto, previsto per l'inizio del 2025, fornirà esclusività sul mercato fino al 2043 per i programmi anti-cancro AccuTOX® e ARM® di Defence.
L'azienda ha anche ottenuto il brevetto statunitense 12,150,989 il 26 novembre 2024, estendendo la protezione delle varianti potenzianti l'immunogenicità a base di Accum® a composti a base di acidi steroidei. Inoltre, una domanda di brevetto Singaporeano è stata recentemente approvata ed è prevista l'emissione per l'inizio del 2025.
Questi sviluppi rafforzano la posizione della proprietà intellettuale di Defence per la concessione di licenze e le partnership strategiche, in particolare per migliorare la potenza dei vaccini. L'azienda prevede ulteriori registrazioni di brevetti nazionali nel terzo trimestre del 2025 tramite la domanda PCT PCT/CA2023/051758.
Defence Therapeutics (DTCFF) ha fortalecido su cartera de patentes con múltiples emisiones y aprobaciones clave de patentes. La USPTO emitió un Aviso de Aprobación para la solicitud de patente estadounidense 18/318,384, presentada en mayo de 2023, que cubre dimers y multimers basados en Accum®. Esta patente, que se espera para principios de 2025, proporcionará exclusividad en el mercado hasta 2043 para los programas contra el cáncer AccuTOX® y ARM® de Defence.
La compañía también obtuvo la patente estadounidense 12,150,989 el 26 de noviembre de 2024, ampliando la protección de las variantes que mejoran la inmunogenicidad basadas en Accum® a compuestos basados en ácidos esteroides. Además, una solicitud de patente en Singapur fue recientemente aprobada y se espera que sea concedida a principios de 2025.
Estos desarrollos fortalecen la posición de Defence en la propiedad intelectual para licencias y asociaciones estratégicas, particularmente en la mejora de la potencia de las vacunas. La compañía planea presentaciones adicionales de patentes nacionales en el tercer trimestre de 2025 a través de la solicitud PCT PCT/CA2023/051758.
Defense Therapeutics (DTCFF)는 여러 주요 특허 발급 및 승인으로 특허 포트폴리오를 강화했습니다. USPTO는 2023년 5월에 제출된 미국 특허 신청 18/318,384에 대해 승인 통지를 발급하였으며, 이는 Accum® 기반의 이머 및 멀티머를 포함합니다. 이 특허는 2025년 초에 예상되며, Defense의 AccuTOX® 및 ARM® 암 치료 프로그램에 대해 2043년까지 시장 독점권을 제공합니다.
회사는 또한 2024년 11월 26일에 미국 특허 12,150,989를 확보하여, Accum® 기반의 면역원성 강화 변종에 대한 보호를 스테로이드 산 기반의 화합물로 확장했습니다. 또한 최근 싱가포르의 특허 신청이 허가되어 2025년 초에 발급될 것으로 예상됩니다.
이러한 발전은 백신 효능을 개선하는 데 특히 유리한 라이센스 및 전략적 파트너십을 위한 Defense의 지적 재산 위치를 강화합니다. 회사는 PCT 신청 PCT/CA2023/051758을 통해 2025년 3분기에 추가적인 국가 특허 출원을 계획하고 있습니다.
Defence Therapeutics (DTCFF) a renforcé son portefeuille de brevets avec plusieurs émissions et autorisations clés. L'USPTO a délivré un Avis d'Autorisation pour la demande de brevet américain 18/318,384, déposée en mai 2023, couvrant des dimères et multimères à base d'Accum®. Ce brevet, prévu pour début 2025, fournira une exclusivité sur le marché jusqu'en 2043 pour les programmes anticancéreux AccuTOX® et ARM® de Defence.
L'entreprise a également obtenu le brevet américain 12,150,989 le 26 novembre 2024, étendant la protection des variantes améliorant l'immunogénicité basées sur Accum® aux composés à base d'acides stéroïdiens. De plus, une demande de brevet à Singapour a récemment été approuvée et devrait être accordée au début de 2025.
Ces développements renforcent la position de la propriété intellectuelle de Defence pour les licences et les partenariats stratégiques, notamment pour améliorer la puissance des vaccins. L'entreprise prévoit des dépôts de brevets nationaux supplémentaires au troisième trimestre de 2025 via la demande PCT PCT/CA2023/051758.
Defence Therapeutics (DTCFF) hat sein Patentportfolio durch mehrere wichtige Patentveröffentlichungen und Genehmigungen gestärkt. Das USPTO hat eine Mitteilung über die Genehmigung für die US-Patentanmeldung 18/318,384, die im Mai 2023 eingereicht wurde, erlassen, die sich auf Accum®-basierte Dimere und Multimere bezieht. Dieses Patent, das Anfang 2025 erwartet wird, bietet bis 2043 Marktexklusivität für die Anti-Krebs-Programme AccuTOX® und ARM® von Defence.
Das Unternehmen sicherte sich am 26. November 2024 das US-Patent 12,150,989, das den Schutz von Accum®-basierten immunogenen Varianten auf steroide Säure-basierte Verbindungen ausdehnt. Darüber hinaus wurde eine Patentanmeldung in Singapur kürzlich genehmigt und wird voraussichtlich Anfang 2025 erteilt.
Diese Entwicklungen stärken die Position von Defence in Bezug auf geistiges Eigentum für Lizenzen und strategische Partnerschaften, insbesondere bei der Verbesserung der Impfstoffpotenz. Das Unternehmen plant zusätzliche nationale Patentregistrierungen im dritten Quartal 2025 über die PCT-Anmeldung PCT/CA2023/051758.
- USPTO Notice of Allowance received for key patent covering AccuTOX® and ARM® anti-cancer programs
- Market exclusivity secured until 2043 in the US market
- New US patent 12,150,989 granted extending protection for Accum®-based variants
- Additional patent allowance in Singapore strengthening global IP portfolio
- None.
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce the further strengthening of its patent portfolio with several key patent issuances and allowances in multiple jurisdictions.
Upon Defence's striking discovery that multimers based on Accum® variants may exhibit synergistic efficacy and enhanced stability when compared to their monomeric counterparts, Defence filed US patent application no. 18/318,384 (the '384 application) in May 2023, along with a request for fast-track examination by the USPTO. Defence is now thrilled to announce that the USPTO issued a Notice of Allowance on October 17, 2024, with the US patent expected to issue in early 2025 upon payment of the requisite governmental fees. The allowance of the '384 application is noteworthy for Defence's current clinical programs and business strategy on several fronts. First, the allowed application contains valuable composition-of-matter claims covering Accum®-based dimers and multimers, which cover the molecular entities ready for clinical development under Defence's flagship AccuTOX® and ARM® anti-cancer programs. The claims cover the dimers and multimers used alone or conjugated to antigens, carriers, or antibodies, the latter of which is actively being investigated by Defence for the development of novel ADCs. Second, the issuance of the US patent stemming from the '384 application will provide a long period of market exclusivity for Defence in the largest global commercial market for innovative anti-cancer therapeutics, with a projected patent expiry date in 2043. Third, the allowance by the USPTO provides validation from a major patent office of the efficacy, innovative nature, and patentability of Defence's Accum®-based dimer and multimer technology, which bodes well for the company's other national filings planning in Q3 of 2025 stemming from corresponding international (PCT) patent application no. PCT/CA2023/051758.
Defence is also pleased to announce the further strengthening of its patent portfolio covering its platform vaccine technology based on covalent conjugation of Accum® and its variants to enhance immunogenicity of vaccines. In addition to patents already secured for this technology in the United States, Canada, Australia, and Japan, Defence now adds US patent no. 12,150,989 (the '989 patent) that was issued on November 26, 2024. The '989 patent, which includes composition-of-matter coverage, extends Defence's protection of its Accum®-based immunogenicity-enhancing variants to ones based on any steroid acid. Furthermore, Defence is also pleased to disclose that the counterpart Singaporean application no. 11202304388T was recently allowed by the Singaporean Patent Office, and the Singaporean patent is expected to be granted in early 2025 upon payment of the requisite governmental fees. These positive developments demonstrate Defence's continued commitment to strengthening its intellectual property, paving the way for licensing and strategic partnerships, for example, to improve the potency of vaccines already approved or currently in development.
"The recent issuance of these patents and allowances with broad claims covering our leading clinical candidates validates the innovative nature and the strength of our efficacy results, as we remain committed to the development of novel therapeutics for cancers. In addition, it secures Defence to negotiate licensing agreements with strong Biotech and Pharma companies," says Mr. Plouffe, CEO and president of Defence.
With the recent additions of Dr. Svetlana Selivanova, Dr. Maxime Parisotto and Dr. Elias Theodorou to its leadership team, and the fortification of its patent portfolio, foundations have been laid for Defence to build upon a very productive end of 2024, enabling the company to take major leaps forward in 2025 and bring Defence closer to its promise of bring to market novel anti-cancer therapies to improve the lives of patients worldwide.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235990
FAQ
When will Defence Therapeutics' (DTCFF) new US patent application 18/318,384 be issued?
How long will DTCFF's market exclusivity last under the new US patent?
What technologies are covered by DTCFF's new patent application 18/318,384?
When was Defence Therapeutics' (DTCFF) US patent 12,150,989 issued?
When is DTCFF planning additional patent filings through PCT application?
